Drugs in Dev. Nephrology
Phase III
United Kingdom 
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on CRYSTALIZE Evidence Trials
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anifrolumab
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
Details : The Phase II results of Saphnelo (anifrolumab) in lupus nephritis provided important evidence suggesting that blocking type I interferons is a potentially promising strategy for the treatment of lupus nephritis.
Product Name : Saphnelo
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Anifrolumab
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anifrolumab
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AstraZeneca is exploring the potential of Saphnelo (anifrolumab) in a variety of diseases in which type I interferon (IFN) plays a key role, including lupus nephritis, cutaneous lupus erythematosus and myositis.
Product Name : Saphnelo
Product Type : Antibody
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Anifrolumab
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAPA-CKD Phase III trial showed that Farxiga, on top of standard of care consisting of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, reduced the risk of worsening renal function or risk of cardiovascular or renal death by...
Product Name : Farxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the subgroup analysis, compared to placebo Farxiga showed a relative risk reduction of 37% for patients whose CKD was primarily driven by diabetic kidney disease; 57% for glomerulonephritis; and 42% for CKD of other or unknown causes.
Product Name : Farxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AstraZeneca's Farxiga Improves Survivalinn Kidney Disease Patients Study Shows
Details : Results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo...
Product Name : Farxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2020
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Farxiga Phase III DAPA-CKD Trial Paradigm-Shifting Data to Be Presented at ESC 2020
Details : Farxiga shows significant benefit across all primary and secondary endpoints in patients with chronic kidney disease with and without type-2 diabetes .
Product Name : Farxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2020
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FARXIGA significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type 2 diabetes.
Product Name : Farxiga
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on a conclusive signal of efficacy in the prevention of the prim...
Product Name : Invokana
Product Type : HPAPI
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
